Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies (Q34367804)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

12

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

8

object named as

Stefan Faderl

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Srdan Verstovsek

7

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

13

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Guillermo Garcia-Manero

9

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

William Plunkett

3

object named as

William Plunkett

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

10

object named as

Alan F List

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Jeffrey E Lancet

14

object named as

Jeffrey E Lancet

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

2

object named as

Asifa Malik

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

11

object named as

Said Sebti

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Deepa Sampath

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Billie Nowak

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Betsy Williams

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Michelle Burton

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

6 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Leukemia Research

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1461-1467

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Therapeutic Advances in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

FLT3 inhibitors for the treatment of acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Receptor tyrosine kinase alterations in AML - biology and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Adult acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Role of FLT3 in leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Regulation of cell death protease caspase-9 by phosphorylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Clinical experience with fludarabine in hemato-oncology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

New chemotherapeutic agents in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

6 July 2018

Evolving strategies in the treatment of MDS and AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

27 October 2018

AKT signaling in normal and malignant cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

27 October 2018

Regulation of Akt/PKB Ser473 phosphorylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

27 October 2018

PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

27 October 2018

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

27 October 2018

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

27 October 2018

Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

27 October 2018

Survival of acute myeloid leukemia cells requires PI3 kinase activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

27 October 2018

Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205589

27 October 2018

Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23993427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of the metabolites of an antitumor tricyclic nucleoside (NSC-154020)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23993427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23993427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23993427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23993427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response

1 reference

https://pubmed.ncbi.nlm.nih.gov/23993427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23993427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.LEUKRES.2013.07.034

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34367804&oldid=2143958369"